Avalo Therapeutics (AVTX) Retained Earnings (2014 - 2026)
Avalo Therapeutics (AVTX) posted Retained Earnings of -$468.2 million for Q1 2026, down 688558.82% on a QoQ basis from $68000.0 in Q4 2025, and down 192.52% year-over-year from $506.0 million in Q1 2025.
Avalo Therapeutics (AVTX) Retained Earnings (2014 - 2026) Analysis & Trends
Avalo Therapeutics' Retained Earnings history runs 13 years deep, the most recent figure standing at -$468.2 million for Q1 2026.
- Quarterly Retained Earnings fell 192.52% year-over-year to -$468.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$468.2 million (down 192.52% YoY) and the FY2025 annual result came in at $68000.0, up 100.02% from the prior year.
- Retained Earnings was -$468.2 million for Q1 2026 at Avalo Therapeutics, down from $68000.0 in the prior quarter.
- Across five years, Retained Earnings topped out at $508.8 million in Q2 2025 and bottomed at -$468.2 million in Q1 2026.
- A 5-year average of $13.8 million and a median of $68000.0 in 2025 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2023 — Retained Earnings soared 216.15% — and 2025, when it slumped 222.14%.
- Avalo Therapeutics' Retained Earnings stood at -$303.8 million in 2022, then decreased by 10.31% to -$335.1 million in 2023, then declined by 10.48% to -$370.3 million in 2024, then soared by 100.02% to $68000.0 in 2025, then sank by 688558.82% to -$468.2 million in 2026.
- Business Quant data shows AVTX's Retained Earnings at -$468.2 million in Q1 2026, $68000.0 in Q4 2025, and -$434.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Avalo Therapeutics | 1.04 Mn | 1.04 Mn | - | -468.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -468.15 Mn |
| Dec 31, 2025 | 68,000.00 |
| Sep 30, 2025 | -434.80 Mn |
| Jun 30, 2025 | 508.77 Mn |
| Mar 31, 2025 | 506.02 Mn |
| Dec 31, 2024 | -370.26 Mn |
| Sep 30, 2024 | 355.99 Mn |
| Jun 30, 2024 | 344.35 Mn |
| Mar 31, 2024 | 343.88 Mn |
| Dec 31, 2023 | -335.13 Mn |
| Sep 30, 2023 | 341.47 Mn |
| Jun 30, 2023 | 314.76 Mn |
| Mar 31, 2023 | 307.50 Mn |
| Dec 31, 2022 | -303.82 Mn |
| Sep 30, 2022 | -294.00 Mn |
| Jun 30, 2022 | -297.20 Mn |
| Mar 31, 2022 | -284.22 Mn |
| Dec 31, 2021 | -262.17 Mn |
| Sep 30, 2021 | -243.00 Mn |
| Jun 30, 2021 | -225.58 Mn |